Cross Cancer Institute, University of Alberta

Edmonton, Alberta T6G 1Z2

2 studies enrolling now · 8 studies all time

What they study most

Adenocarcinoma, Advanced Tumors, Carcinoma, Non-Small-Cell Lung, Metastatic Solid Tumors, Metastatic Uveal Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Non-small Cell Lung Cancer, Solid Tumours

Studies at this site

• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Recruiting now
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• Selinexor and Backbone Treatments of Multiple Myeloma Patients — Recruiting now
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Running, not enrolling
• Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours — Completed
• This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. — Completed
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma — Completed
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed